SCHEMBL2071241

SCHEMBL2071241

COc1cnc(-c2ccccc2)nc1Cl

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.68
ALDH1A1 P00352 7/20 0.59
MAPT P10636 6/20 0.59
L3MBTL1 Q9Y468 2/20 0.57
MEN1 O00255 6/20 0.56
POLB P06746 2/20 0.56
NPSR1 Q6W5P4 2/20 0.54
TRPM8 Q7Z2W7 1/20 0.52
DHPS P49366 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
GLA P06280 1/20 0.47
GAA P10253 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
PDGFRB P09619 1/20 0.47
PDGFRA P16234 1/20 0.47
LMNA P02545 1/20 0.46
HTT P42858 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20798631 0.85 PDGFRB (0.49) KMT2AALDH1A1MAPTL3MBTL1MEN1
SCHEMBL1444026 0.84 ALDH1A1 (0.50) KMT2AALDH1A1MAPTMEN1POLB
SCHEMBL25225516 0.83 ALDH1A1 (0.55) KMT2AALDH1A1MAPTL3MBTL1MEN1
SCHEMBL27890295 0.82 PDGFRB (0.57) KMT2AALDH1A1MAPTL3MBTL1MEN1
SCHEMBL23111089 0.81 MAPT (0.47) KMT2AALDH1A1MAPTL3MBTL1MEN1
SCHEMBL25719741 0.81 KMT2A (0.70) KMT2AALDH1A1MAPTL3MBTL1MEN1
SCHEMBL15614430 0.81 KMT2A (1.00) KMT2AALDH1A1MAPTL3MBTL1MEN1
SCHEMBL5252239 0.79 KMT2A (0.68) KMT2AALDH1A1MAPTL3MBTL1MEN1
SCHEMBL25277671 0.79 KMT2A (0.68) KMT2AALDH1A1MAPTL3MBTL1MEN1
SCHEMBL10647644 0.79 PDE5A (0.47) KMT2AALDH1A1MAPTL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353851-A1 PURINES AND METHODS OF THEIR USE KINETA INC (US) 2025-11-20 US disclosed
US-20250288589-A1 PYRIDOPYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. 2025-09-18 US disclosed
CN-119031913-A Purine and methods of use thereof 奇尼塔公司 2024-11-26 CN disclosed
EP-4444312-A2 PURINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2024-10-16 EP disclosed
EP-4444289-A1 PYRIDOPYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2024-10-16 EP disclosed
WO-2023107552-A2 PURINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 WO disclosed
WO-2023107592-A1 PYRIDOPYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 WO disclosed
WO-2023107592-A1 PYRIDOPYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 WO disclosed
WO-2023107552-A2 PURINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 WO disclosed
US-7902373-B2 asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide PFIZER INC (US) 2011-03-08 US disclosed
EP-2129660-A2 NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES Pfizer Products Inc. (US) 2009-12-09 EP disclosed
WO-2008075172-A2 NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES PFIZER PRODUCTS INC. (US) 2008-06-26 WO disclosed
US-20080146569-A1 Nicotinamide Derivatives PFIZER INC. 2008-06-19 US disclosed
WO-1992005159-A1 2-PHENYL-PYRIMIDINES, PROCESS FOR PRODUCING THE SAME, AGENTS CONTAINING THE SAME AND THEIR USE AS FUNGICIDES HOECHST AKTIENGESELLSCHAFT (DE) 1992-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250288589-A1 PYRIDOPYRIMIDINES AND METHODS OF THEIR USE PNPO, DPYD, PYGB KMT2A 2619/4885ALDH1A1 945/4885MAPT 227/4885
US-20080146569-A1 Nicotinamide Derivatives NNT, NAMPT, NADK KMT2A 2987/4885ALDH1A1 148/4885MAPT 1563/4885
US-20250353851-A1 PURINES AND METHODS OF THEIR USE TDP1, TDP2, PIKFYVE KMT2A 1961/4885ALDH1A1 4617/4885MAPT 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.